International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 523-526 doi: 10.5281/zenodo.16810986
Original Article
Outcome of Laparoscopic Cholecystectomy in Post ERCP Patients: A Retrospective Study
 ,
 ,
Published
Aug. 12, 2025
Abstract

Background: Laparoscopic cholecystectomy (LC) is the preferred surgical approach for symptomatic gallstones. In cases of choledocholithiasis, preoperative endoscopic retrograde cholangiopancreatography (ERCP) is performed for common bile duct (CBD) clearance. However, ERCP-induced inflammation and fibrosis may complicate subsequent LC.

Objective: To assess the safety, feasibility, and outcomes of LC performed after successful ERCP for CBD stone clearance.

Methods: A retrospective analysis was conducted on 157 patients undergoing LC following ERCP from January 2021 to July 2025 at GMC Srinagar. Data collected included patient demographics, ERCP characteristics, interval between ERCP and LC, intraoperative findings, and postoperative outcomes.

Results: The cohort had a female predominance (66.9%) with a mean age of 45.7 ± 12.4 years. The interval between ERCP and LC averaged 6.3 ± 3.1 weeks. LC duration averaged 68 ± 21 minutes. Intraoperative complications included hemorrhage (2.5%) and gallbladder perforation (7%). Postoperative complications were low: surgical site infection (4.4%) and residual CBD stones (2.5%). No bile duct injury, bile leak, conversion to open surgery, or mortality was observed. Operative difficulty was noted in 29% of cases based on adhesions and distorted Calot’s triangle.

Conclusion: LC post ERCP is safe and feasible when performed by experienced surgeons. A waiting interval of 4–6 weeks may optimize operative conditions and reduce perioperative risk.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
830 Views
431 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved